• QuIC-ConCePT
    • Welcome
    • About QuIC-ConCePT
    • QuIC-ConCePT Partners
    • Project management
    • Slideshow images
  • FAQs
    • 1. What is IMI
    • 2. What is QuIC-ConCePT
    • 3. What is a biomarker?
    • 4. What are biomarker “validation” and “qualification”?
    • 5. What are the advantages of imaging biomarkers?
    • 6. What special considerations pertain to imaging biomarkers?
    • 7. What is the unmet need for IBs in oncology?
    • 8. What is the vision for QuIC-ConCePT?
    • 9. What IBs will QuIC-ConCePT qualify?
    • 10. What work will QuIC-ConCePT undertake?
    • 11. Where can I learn more?
  • Workpackages
    • Work Package 1
    • Work Package 2
    • Work Package 3
    • Work Package 4
    • Work Package 5
    • Work Package 6
  • Achievements
  • Publications
    • Peer Reviewed Publications
    • Conference Abstracts
    • Presentations
      • Reducing Attrition Rates in Anticancer Drug Discovery and Development: IMI Approaches
  • Meetings
  • No categories

FAQs

Frequently Asked Questions:

  1. What is IMI?
  2. What is QuIC-ConCePT?
  3. What is a biomarker?
  4. What are biomarker “validation” and “qualification”?
  5. What advantage from Imaging Biomarkers?
  6. What special considerations pertain to imaging biomarkers?
  7. What is the unmet need for imaging biomarkers in oncology?
  8. What is the vision for QuIC-ConCePT?
  9. What Imaging Biomarkers will QuIC-ConCePT qualify?
  10. What work will QuIC-ConCePT undertake?
  11. Where can I learn more?

IMI oncology projects

  • ONCOTRACK
  • PREDECT
  • QuIC-ConCePT QuIC-ConCePT

Disclaimer

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking (www.imi.europa.eu) under grant agreement number 115151, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This presentation reflects the authors’ view and neither IMI JU nor the European Union and EFPIA are liable for any use that may be made of the information contained herein